Clinical Trials Logo

Anticholinergic Toxicity clinical trials

View clinical trials related to Anticholinergic Toxicity.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06399679 Not yet recruiting - Clinical trials for Anticholinergic Toxicity

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

RIVA-AP
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine is effective in reversing AMD but has a short duration of action, and patient commonly experience recurrence of AMD after initial control with physostigmine. Recent case reports and small observational studies suggest that rivastigmine, which has a longer duration of action than physostigmine, might be useful in the treatment of AMD. In order to investigate the effectiveness of rivastigmine in preventing recurrence of AMD after initial control with physostigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine after initial control of AMD with physostigmine will experience less recurrence of antimuscarinic delirium than those treated with placebo.

NCT ID: NCT06382649 Not yet recruiting - Clinical trials for Anticholinergic Toxicity

Rivastigmine for Antimuscarinic Delirium

RIVA-AM
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine, the standard antidote for AMD, currently has very limited availability in the United States due to an interruption of production. Recent case reports and small observational studies suggest that rivastigmine might be useful in the treatment of AMD, but there is not direct prospective evidence comparing rivastigmine to physostigmine or supportive care. In order to investigate the effectiveness of rivastigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine for antimuscarinic delirium will experience more rapid resolution of agitation and delirium than those treated with placebo.